NCLT: Suspended Directors Who are Prospective Resolution Applicants Cann’t Access Valuation Reports  ||  Supreme Court Clarifies Test For Granting Bail to Accused Added at Trial under Section 319 CrPC  ||  SC: Fresh Notification For Vijayawada ACB Police Station not Required After AP Bifurcation  ||  SC: Studying in a Government Institute Does Not Create an Automatic Right to a Government Job  ||  NCLT Mumbai: CIRP Claims Cannot Invoke the 12-Year Limitation Period For Enforcing Mortgage Rights  ||  NCLAT: Misnaming Guarantor as 'Director' in SARFAESI Notice Doesn't Void Guarantee Invocation  ||  Jharkhand HC: Mere Breach of Compromise Terms by an Accused Does Not Justify Bail Cancellation  ||  Cal HC: Banks Cannot Freeze a Company's Accounts Solely Due To ROC Labeling a 'Management Dispute'  ||  Rajasthan HC: Father’s Rape of His Daughter Transcends Ordinary Crime; Victim’s Testimony Suffices  ||  Delhi HC: Judge Who Reserved Judgment Must Deliver Verdict Despite Transfer; Successor Can't Rehear    

SEBI Imposes Rs. 22 Crore fine on Aurobindo Pharma for Insider Trading - (24 Sep 2019)

CAPITAL MARKET

Securities and Exchange Board of India has imposed a fine of Rs. 22.7 crore on Aurobindo Pharma Ltd., its promoters and related entities for insider trading between July, 2008 to March, 2009.

Tags : SECURITIES AND EXCHANGE BOARD OF INDIA   AUROBINDO PHARMA LTD.  SEBI  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved